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or best supportive care (BSC). Methods: The BIM was developed from the UK 
NHS (National Health Service) and Personal and Social Services (PSS) perspective. 
The status quo scenario assumed the three BoNT-As, Dysport® (abobotulinum-
toxinA), Botox® (onabotulinumtoxinA), or Xeomin® (incobotulinumtoxinA), are 
used in 33%, 52% and 15%, respectively, of patients with ULS receiving BoNT-A 
in the UK. The new market share scenario assumed an increased proportional 
use of abobotulinumtoxinA (to 73% in year 5) compared to other interventions. 
The patients were modelled over a 5-year horizon. Epidemiologic data inputs 
were from published sources. Unit costs for BoNT-As, other health care costs and 
non-medical costs came from the British National Formularyand PSS. Resource-use 
inputs were obtained from UK clinicians. One-way sensitivity analyses for model 
inputs were conducted. Results: Total care costs were decreased by between 
£425,765 in year 2 and £1,854,601 in year 5 by shifting market share to abobo-
tulinumtoxinA. In the base-case scenario, BSC (no BoNT-A treatment) or with 
incobotulinumtoxinA or onabotulinumtoxinA cost more per patient per year than 
abobotulinumtoxinA. Sensitivity analyses showed that number of patients treated 
with BoNT-As, time-to-re-injection, and dose per injection of abobotulinumtoxinA 
and onabotulinumtoxinA were the most influential parameters on budget impact, 
impacting both drug acquisition costs and physician visits. ConClusions: Study 
findings suggest that increased use of abobotulinumtoxinA compared with inco-
botulinumtoxinA and onabotulinumtoxinA for ULS in the UK could potentially 
reduce total treatment costs.
PND14
The BuDgeT ImPacT of INTroDucINg Bg-12 (DImeThyl fumaraTe) for 
TreaTmeNT of relaPse-remITTINg mulTIPle sclerosIs (rrms) IN caNaDa
Dorman E.1, Kansal A.R.1, Sarda S.2
1Evidera, Bethesda, MD, USA, 2Biogen Idec, Weston, MA, USA
objeCtives: Multiple sclerosis causes significant disability and mortality globally 
and is especially prevalent in Canada and across Europe. BG-12 is an orally admin-
istered disease modifying treatment for relapsing-remitting MS (RRMS) patients 
currently on the market in the United States and Canada and under review in 
Europe. A budget impact model (BIM) was developed to assess the financial con-
sequences of introducing BG-12 for the treatment of RRMS in Canada. Methods: 
A BIM calculated the financial consequences of introducing BG-12 in Canada over 
three years based on RRMS prevalence, treatment market share, and clinical effects. 
RRMS prevalence in Canada was derived from published literature and natural 
relapse rates and disease state distribution from clinical trial data. It was conserva-
tively assumed that 100% of RRMS patients were treated with a disease modifying 
treatment. BG-12 was assumed to absorb market share proportionally from the 
following current treatments: interferon beta-1a IM, interferon beta-1a SC, inter-
feron beta-1b, glatiramer acetate, natalizumab, and fingolimod. Treatment efficacy, 
in terms of reductions in relapse rate, and treatment discontinuation rates were 
determined from a mixed treatment comparison. Treatment costs (including costs 
of acquisition, monitoring, and administration) and the cost of relapse were con-
sidered. Deterministic one-way sensitivity analyses were conducted to assess the 
most sensitive input parameters. Results: Over three years, the introduction of 
BG-12 resulted in an average annual increase of CAD279 per treated patient per year, 
with reductions in costs associated with relapses (CAD192/patient/year) partially 
offsetting increased drug acquisition costs (CAD471/patient/year). On a popula-
tion level, the average annual cost increase was CAD16,494,850. The main drivers 
of budget impact were cost of BG-12, drop-out rates, proportion of RRMS patients 
treated, and market share assumptions. ConClusions: The acquisition costs of 
BG-12 for treatment of RRMS are predicted to be partially offset by reduced costs of 
relapses in the Canadian health care system.
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objeCtives: AMLs are benign tumors common in patients with TSC, associated 
with high morbidity (aneurysm, hemorrhage, chronic kidney disease), and can 
result in death. Complication risk may correlate with increased AML volume. 
Historically, AMLs were treated surgically with embolization or tissue-sparing 
resection. In the EXIST-2 trial, everolimus significantly reduced AML volume in 
TSC patients. This analysis estimates the cost of reimbursing everolimus for TSC-
related AML to the UK health care system. Methods: A Markov model was built to 
analyze budget impact over five years. The treated population is estimated using 
TSC and AML prevalence. Adult patients with growing AML ≥ 3 cm are assumed 
eligible for everolimus. Treatment reference costs are from the UK, resource utili-
zation data from The Netherlands, efficacy and safety assumptions from EXIST-2. 
The model assumed one-year treatment duration. Responding patients (≥ 30% 
AML volume reduction) may restart everolimus upon AML regrowth. Costs are 
discounted at 3.5% per annum. Sensitivity analyses were conducted. Results: 
Up to 1,474 adults in the UK have TSC-related AML; 30% are assumed eligible 
for everolimus. On average, 165 patients are estimated to be treated annually 
with everolimus (Year 1: 88; Year 5: 233) at an average cost of £4,600,000 (Year 
1: £2,700,000; Year 5: £6,200,000). Over five years, AML-related medical spending 
decreased £54,000. Annual per patient treatment cost with everolimus is £31,000. 
Results were most sensitive to patient prevalence, percent eligible for everolimus, 
and the percent experiencing ≥ 30% AML volume reduction. ConClusions: TSC 
is a relatively rare genetic disease for which everolimus is the only non-surgical 
treatment that has demonstrated efficacy in reducing AML volume. Reducing AML 
volume may prevent long-term complications and avoid surgeries, resulting in 
decreased AML-related medical costs. Further long-term studies are needed to 
better understand the benefits of everolimus in preventing AML-related morbidity 
and the associated costs.
days, respectively. By frequency of outpatient appointments a combined generic drug 
fezam (234 appointments, prise $ 5.1), and outpatient cavinton (19 appointments, 
prise $ 17.27) were used often. ConClusions: In Ukraine, outpatient cerebroprotec-
tive drugs consumption is greater than their consumption in hospital due to the lack 
of prescriptions control.
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objeCtives: Spasticity is a common condition among patients with progres-
sive and/or relapsing forms of multiple sclerosis (MS). Current therapies seem to 
partially control spasticity symptoms, and patients often receive multiple treat-
ments or switch to new treatments to achieve a better control. The objective of 
this analysis was to assess the current usage of spasticity drugs and relative 
patterns of utilization among patients with MS, through administrative database 
analysis. Methods: Using DENALI datawarehouse, we detected MS patients 
who, during the period January 2000 – December 2009, had at least one disease 
modifying agent (DMA) prescription Then the usage of drugs commonly used 
in spasticity (muscle relaxant drugs, baclofen, tizanidine, clonidine, dantrolene) 
was evaluated in this cohort of patients, in terms of number of subjects receiving 
at least one prescription, and number of DDD (defined daily doses) per patient 
per year. Results: From 2000 to 2009, the annual number of patients with MS, 
receiving DMA treatment raised from 10,746 to 12,594. Concomitantly, the annual 
number of patients receiving at least one muscle relaxant prescription raised from 
5.87% (n= 631) to 9.42% (n= 1,186). The most prescribed drug was baclofen with few 
patients receiving other drugs commonly indicated in spasticity (dantrolene, tiza-
nidine and clonidine). A relevant number of patients using muscle relaxants also 
received other drugs for the central nervous system, although its usage achieved 
a peak in 2005 (8% of MS patients). The analysis of DDD per patient/year suggested 
that the usage of muscle relaxant might be almost chronic in these patients (in 
2009, 303 DDD per patients per year). ConClusions: Only 10% of patients with 
MS currently receive active pharmacological treatment, although this condition 
seems affecting more than 20% of MS patients in Europe. Also, there are not rel-
evant alternatives or second line options to baclofen, which is the most commonly 
prescribed drug in this condition.
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objeCtives: Few studies have assessed the prevalence and incidence of Parkinson’s 
disease (PD) in France. The objectives of this study were to estimate the prevalence 
and incidence of PD between 2005 and 2010 using a claims and hospitalisations 
database. Methods: The EGB database is a 1/97 permanent random sample of 
the French health care insurance system database linked to the national hospital 
discharge summary database. Data for all adults with full insurance coverage for 
PD, or hospitalised with main, related, or associated PD diagnosis, or with at least 3 
antiparkinson agent reimbursements over a one-year period were extracted for the 
years 2004 to 2010. A specific and a sensitive PD criterion were defined: i) patients 
with a medical diagnosis of PD from full insurance coverage or hospitalisation; ii) 
same patients plus those without a PD medical diagnosis in the database but a 
drug pattern compatible with this diagnosis (a second set of at least 3 antiparkin-
son agent reimbursements over another one-year period and no co-medication 
with extrapyramidal side effects, as well as no antiparkinson agent pattern spe-
cific of another indication). EGB estimations were applied to the French population 
with age and gender standardization to estimate the prevalence and incidence in 
France. Results: Prevalence of PD increased from 0.27% in 2005 to 0.33% in 2010 
using the specific definition of disease, and from 0.38% to 0.46% using the sensitive 
definition. The incidence rate per year was 0.03-0.04% using the specific definition 
of disease, and 0.05-0.06% using the sensitive definition. Estimated population size 
was between 180,000 and 255,000 persons in 2010 with approximately 22,000 to 
32,000 new patients per year. ConClusions: The prevalence and incidence of PD 
in France are likely to be within the range of estimations found in the EGB database 
using the specific and sensitive definitions of disease; results are consistent with 
that reported internationally.
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objeCtives: Upper limb spasticity (ULS) secondary to upper motor neurone 
lesions has a considerable patient and caregiver burden, particularly with regards 
to pain, activities of daily living and personal care. BotulinumtoxinA (BoNT-A) 
injections are effective in treating ULS. We developed a budget impact model 
(BIM) to assess different BoNT-A treatments available in the UK for reducing 
ULS. We also assessed annual costs of treating each ULS patient with BoNT-A 
